医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Rubicon Research Acquires Impopharma Canada

2020年01月07日 PM09:00
このエントリーをはてなブックマークに追加


 

MUMBAI, India

As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, today announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.

Impopharma offers comprehensive drug product formulation and process development, as well as wide-ranging analytical testing services to the pharmaceutical industry, specializing in nasal and pulmonary drug products. Over the next several months, the Company plans to establish development plans for a mix of both internal and external development projects.

“I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together,” said Parag Sancheti, Rubicon’s Chief Executive Officer.

The 13,000 sq. ft. Impopharma site in Concord, near Toronto, has been previously inspected by the U.S. FDA and Health Canada and will be the nasal and pulmonary development Center of Excellence in the Rubicon network.

Impopharma Canada has been merged with Rubicon Research Canada Limited, a wholly owned subsidiary of Rubicon Research Private Limited.

About Rubicon Research

Rubicon is a responsible partner to global healthcare innovators that design and deliver quality products for making patients’ lives healthy and happy. Rubicon also develops and commercializes its own value added formulations in the global market. Rubicon currently has several commercial products in the global market and a pipeline of over 60 products in development or under review. Rubicon holds more than 50 issued patents in drug delivery technologies and with its new R&D center can develop pharmaceutical products across dosage forms. The manufacturing facility located in Ambernath (India) has global regulatory approvals for commercial supply of oral solid dosage forms. Rubicon also has a marketing office based in New Jersey, USA.

Rubicon is a portfolio company of General Atlantic, a global growth equity investor with nearly USD 35 billion in assets under management.

Through its “Grow Together” initiative, Rubicon provides capital and strategic support to seed and early-stage ventures founded by entrepreneurs and innovators in the traditional pharmaceutical domain as well as allied domains involving the application of emerging technologies like artificial intelligence, continuous manufacturing and big data in the pharmaceutical industry, to achieve Rubicon’s key goals of Innovation, Quality and Care.

For additional information, please visit www.rubicon.co.in/venture

View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005135/en/

CONTACT

Vien Brewster
General Manager, Rubicon Research Canada
vien.brewster@rubicon-canada.com

Sagar Oak
Director – Corporate Development, Rubicon Research
sagar.oak@rubicon.co.in

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • JEOL:发布新的扫描电子显微镜JSM-IT700HR
  • Asahi Kasei Providing Samples of Hyaluronic Acid Nanogel as a New Pharmaceutical Excipient
  • PHC株式会社:オンライン資格確認へ対応する、PHCの医療機関・保険薬局向け医事コンピューターとパナソニックの「顔認証付きカードリーダー(マイナンバーカード対応)」とのシステム連携について
  • Evaluate新レポート:COVID-19パンデミック下でさえ、革新的で有効な治療薬に対する需要は続く
  • Cellix Bio Pharma Completes the Acquisition of Avaca Pharma